Now showing items 1-10 of 10

    • Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma 

      Gill, Sonja J.; Travers, Jon; Pshenichnaya, Irina; Kogera, Fiona A.; Barthorpe, Syd; Mironenko, Tatiana; Richardson, Laura; Benes, Cyril H.; Stratton, Michael R.; McDermott, Ultan; Jackson, Stephen P.; Garnett, Mathew J. (Public Library of Science, 2015)
      Ewing’s sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with metastatic or recurrent disease. Ewing’s sarcoma cells are acutely hypersensitive to poly (ADP-ribose) polymerase (PARP) inhibition ...
    • Genomics of Drug Sensitivity in Cancer (GDSC): a Resource for Therapeutic Biomarker Discovery in Cancer Cells 

      Yang, Wanjuan; Soares, Jorge; Greninger, Patricia; Edelman, Elena J.; Lightfoot, Howard; Forbes, Simon; Bindal, Nidhi; Beare, Dave; Smith, James A.; Thompson, I. Richard; Ramaswamy, Sridhar; Futreal, P. Andrew; Haber, Daniel Arie; Stratton, Michael R.; Benes, Cyril Henri; McDermott, Ultan; Garnett, Mathew J. (Oxford University Press, 2012)
      Alterations in cancer genomes strongly influence clinical responses to treatment and in many instances are potent biomarkers for response to drugs. The Genomics of Drug Sensitivity in Cancer (GDSC) database (www.cancerRxgene.org) ...
    • Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors 

      Ducker, Gregory S.; Atreya, Chloe E.; Simko, Jeffry P.; Hom, Yun K.; Matli, Mary R.; Benes, Cyril H.; Hann, Byron; Nakakura, Eric K.; Bergsland, Emily K.; Donner, David B.; Settleman, Jeffrey; Shokat, Kevan M.; Warren, Robert S. (2014)
      The mammalian target of rapamycin (mTOR) regulates cell growth by integrating nutrient and growth factor signaling and is strongly implicated in cancer. But mTOR is not an oncogene, and which tumors will be resistant or ...
    • Integrating Complex Genomic Datasets and Tumour Cell Sensitivity Profiles to Address a 'Simple' Question: Which Patients Should Get this Drug? 

      Benes, Cyril Henri; Settleman, Jeffrey Evan (BioMed Central, 2009)
      It is becoming increasingly apparent that cancer drug therapies can only reach their full potential through appropriate patient selection. Matching drugs and cancer patients has proven to be a complex challenge, due in ...
    • Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer 

      Michaut, Magali; Chin, Suet-Feung; Majewski, Ian; Severson, Tesa M.; Bismeijer, Tycho; de Koning, Leanne; Peeters, Justine K.; Schouten, Philip C.; Rueda, Oscar M.; Bosma, Astrid J.; Tarrant, Finbarr; Fan, Yue; He, Beilei; Xue, Zheng; Mittempergher, Lorenza; Kluin, Roelof J.C.; Heijmans, Jeroen; Snel, Mireille; Pereira, Bernard; Schlicker, Andreas; Provenzano, Elena; Ali, Hamid Raza; Gaber, Alexander; O’Hurley, Gillian; Lehn, Sophie; Muris, Jettie J.F.; Wesseling, Jelle; Kay, Elaine; Sammut, Stephen John; Bardwell, Helen A.; Barbet, Aurélie S.; Bard, Floriane; Lecerf, Caroline; O’Connor, Darran P.; Vis, Daniël J.; Benes, Cyril H.; McDermott, Ultan; Garnett, Mathew J.; Simon, Iris M.; Jirström, Karin; Dubois, Thierry; Linn, Sabine C.; Gallagher, William M.; Wessels, Lodewyk F.A.; Caldas, Carlos; Bernards, Rene (Nature Publishing Group, 2015)
      Invasive lobular carcinoma (ILC) is the second most frequently occurring histological breast cancer subtype after invasive ductal carcinoma (IDC), accounting for around 10% of all breast cancers. The molecular processes ...
    • Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment 

      Friedman, Adam A.; Amzallag, Arnaud; Pruteanu-Malinici, Iulian; Baniya, Subash; Cooper, Zachary A.; Piris, Adriano; Hargreaves, Leeza; Igras, Vivien; Frederick, Dennie T.; Lawrence, Donald P.; Haber, Daniel A.; Flaherty, Keith T.; Wargo, Jennifer A.; Ramaswamy, Sridhar; Benes, Cyril H.; Fisher, David E. (Public Library of Science, 2015)
      A newer generation of anti-cancer drugs targeting underlying somatic genetic driver events have resulted in high single-agent or single-pathway response rates in selected patients, but few patients achieve complete responses ...
    • Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties 

      Menden, Michael P.; Iorio, Francesco; Garnett, Mathew; McDermott, Ultan; Benes, Cyril Henri; Ballester, Pedro J.; Saez-Rodriguez, Julio (Public Library of Science, 2013)
      Predicting the response of a specific cancer to a therapy is a major goal in modern oncology that should ultimately lead to a personalised treatment. High-throughput screenings of potentially active compounds against a ...
    • Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy 

      Choy, Edwin; Butrynski, James E; Harmon, David C; Morgan, Jeffrey A; George, Suzanne; Wagner, Andrew J; D’Adamo, David; Cote, Gregory M; Flamand, Yael; Benes, Cyril H; Haber, Daniel A; Baselga, Jose M; Demetri, George D (BioMed Central, 2014)
      Background: Preclinical studies have documented antitumor activity of PARP inhibition both in vitro and in vivo, against Ewing sarcoma cells. This study aimed to translate that observation into a clinical trial to assess ...
    • Targeting transcription regulation in cancer with a covalent CDK7 inhibitor 

      Kwiatkowski, Nicholas; Zhang, Tinghu; Rahl, Peter B; Abraham, Brian J; Reddy, Jessica; Ficarro, Scott B; Dastur, Anahita; Amzallag, Arnaud; Ramaswamy, Sridhar; Tesar, Bethany; Jenkins, Christopher R; Hannett, Nancy M; McMillin, Douglas; Sanda, Takaomi; Sim, Taebo; Kim, Nam Doo; Look, Thomas; Mitsiades, Constantine; Weng, Andrew P; Brown, Jennifer R; Benes, Cyril H.; Marto, Jarrod A; Young, Richard A; Gray, Nathanael S. (2014)
      Tumor oncogenes include transcription factors that co-opt the general transcriptional machinery to sustain the oncogenic state1, but direct pharmacological inhibition of transcription factors has thus far proven difficult2. ...
    • Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics 

      Chen, Li; Stuart, Lynda; Ohsumi, Toshiro K; Burgess, Shawn; Varshney, Gaurav K; Dastur, Anahita; Borowsky, Mark L; Benes, Cyril Henri; Lacy-Hulbert, Adam; Schmidt, Emmett V (BioMed Central, 2013)
      Background: The development of resistance to chemotherapies represents a significant barrier to successful cancer treatment. Resistance mechanisms are complex, can involve diverse and often unexpected cellular processes, ...